Metformin (also known as Glucophage) has been approved to control blood sugar in the U.S. since the mid-1990s, and it has been used in Europe for more than 50 years.
It is used by millions of people with type 2 diabetes and those at risk for developing the disease.
In the study, Mayo clinic researchers followed 61 women with diabetes taking metformin who also had ovarian cancer, and 178 ovarian cancer patients without diabetes who were not taking the drug.
Even though the metformin-takers and non-takers were matched for age, ovarian cancer stage, and other key variables likely to impact survival, the women who took the drug had improved survival.
After five years, 67% of women who took metformin had not died from ovarian cancer, compared to 47% of women without diabetes who did not take the drug. The researchers also found that among women with diabetes who took insulin or other diabetes drugs, 43% of those taking insulin and 34% of those taking other diabetes drugs had not died from ovarian cancer.
The study was published online today in the journal Cancer.
“The survival difference in the two groups was striking,” says researcher Sanjeev Kumar, MBBS.
William Cliby, MD, agrees. He directs the department of gynecologic surgery at the Mayo Clinic.
While it was not clear if taking the diabetes drug caused the women with diabetes to live longer, Cliby says the data certainly pointed in that direction.
“Every way we looked at this, the metformin group always did better,” he says.